ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

June 27, 2014

Cancer Prevention Grants Awarded To Five States, DC

June 30, 1989

Foundation For COG Is New Name Of NCCF.

October 19, 2001

NCI To Test 5,000 DC-Area Jews To Determine Risk Of BRCA 1 Mutation

October 6, 1995

Rauscher Delays Decision Until June 30

June 11, 1976

ACCP and ASCO Publish Joint Guideline Following Review of Evidence on Low-Dose CT

May 25, 2012